文献速递外周动脉疾病

LIBERTY 360研究:按Rutherford分级分层的外周动脉疾病血管内治疗3年结局

Three-Year Outcomes From the LIBERTY 360 Study of Endovascular Interventions for Peripheral Artery Disease Stratified by Rutherford Category.
PubMed 文献 · J Endovasc Ther · 2020-10-05

LIBERTY 360是一项前瞻性、观察性、核心实验室评估的多中心研究,纳入1189例外周动脉疾病患者,按Rutherford分级(RC 2-3、4-5、6)分层分析血管内治疗后的3年结局。结果显示36个月生存率在RC 2-3、4-5、6组分别为86.0%、79.8%、62.0%,免于大截肢率分别为98.5%、94.0%、79.9%,免于TVR/TLR率分别为71.1%、64.2%、61.9%。所有患者生活质量持续改善至36个月。

要点

  • 血管内治疗后有症状PAD患者36个月生存率随Rutherford分级升高而降低。
  • RC 6患者36个月免于大截肢率仅79.9%,显著低于RC 2-3的98.5%。
  • 所有Rutherford分级患者生活质量改善持续至36个月。

核心结论

  • 血管内治疗是有症状PAD患者的可行治疗选择,跛行和慢性肢体威胁性缺血患者的生活质量均持续改善。

研究设计与样本

  • LIBERTY 360研究为前瞻性、观察性、核心实验室评估的多中心研究,纳入1189例患者,按Rutherford分级分层:RC 2-3(n=500)、RC 4-5(n=589)、RC 6(n=100)。

主要发现

  • 36个月Kaplan-Meier生存率:RC 2-3组86.0%,RC 4-5组79.8%,RC 6组62.0%。
  • 36个月免于大截肢率:RC 2-3组98.5%,RC 4-5组94.0%,RC 6组79.9%。
  • 36个月免于TVR/TLR率:RC 2-3组71.1%,RC 4-5组64.2%,RC 6组61.9%。
  • 基线跛行患者36个月随访期间MAE风险低于RC 4-5和RC 6患者。
  • 所有患者VascuQol-25生活质量评分从基线改善并持续至36个月。

临床怎么用

  • 可为症状性PAD患者选择血管内治疗提供3年中期结局的参考点估计值。
  • 应依据Rutherford分级评估患者长期生存、截肢和再干预风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the 3-year results of the LIBERTY 360 study, which investigated outcomes of endovascular treatment of symptomatic peripheral artery disease (PAD). MATERIALS AND METHODS: The LIBERTY trial (ClinicalTrials.gov identifier NCT01855412) was a prospective, observational, core laboratory-assessed, multicenter study of endovascular interventions enrolling >1200 participants treated at 51 sites. Data from 1189 patients were stratified according to Rutherford category (RC) and analyzed [RC 2-3 (n=500), RC 4-5 (n=589), and RC 6 (n=100)]. The primary outcomes were major amputation of the target limb and all-cause death; secondary outcomes were target vessel revascularization (TVR) or target lesion revascularization (TLR); major adverse events (MAEs; death within 30 days, TVR or TLR, and major amputation); death or major amputation combined; and change in self-reported quality of life (QoL) measures (VascuQol-25). The Kaplan-Meier (KM) method was employed to estimate the outcomes; estimates are presented with the 95% confidence intervals (CI). Predictors of 3-year MAE, death, TVR, and major amputation were analyzed using Cox proportional hazard regression modeling. RESULTS: The 36-month KM survival rates were 86.0% in RC 2-3, 79.8% in RC 4-5, and 62.0% in RC 6 groups. The KM estimates of freedom from major amputation at 36 months were 98.5% in RC 2-3, 94.0% in RC 4-5, and 79.9% in RC 6. The 36-month KM estimates for freedom from TVR/TLR were 71.1% in RC 2-3, 64.2% in RC 4-5 and 61.9% in RC 6 groups. Patients with claudication at baseline were at lower risk for MAEs compared with RC 4-5 and RC 6 patients during the 36-month follow-up. Vascular QoL improved from baseline and persisted up to 36 months in all patients. CONCLUSION: Endovascular therapy is a viable treatment option for patients with symptomatic PAD, with sustained improved quality of life in both claudicants and patients with chronic limb-threatening ischemia. These results provide important point estimates for midterm outcomes after modern endovascular interventions for PAD.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Giannopoulos S, Mustapha J, Gray WA, et al. Three-Year Outcomes From the LIBERTY 360 Study of Endovascular Interventions for Peripheral Artery Disease Stratified by Rutherford Category. J Endovasc Ther. 2020. PMID: 33016805. doi:10.1177/1526602820962972

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。